Companies › Immorna Biotherapeutics
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JCXH-105 srRNA-based vaccine for Herpes Zoster prevention | – | Phase 2 | Herpes Zoster (HZ) | Mar 2027 |
| JCXH-108 mRNA-based vaccine against RSV | – | Phase 1 | Respiratory Syncytial Virus (RSV) | Dec 2026 |
| JCXH-211 PD-1 checkpoint inhibitor | PDCD1 | Phase 1 | Malignant Solid Tumors | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06564194 | JCXH-108 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Dec 2026 |
| NCT06581575 | JCXH-105 | Phase 2 | Herpes Zoster (HZ) | Infectious disease | Mar 2027 |
| NCT06781125 | JCXH-211 | Phase 1 | Malignant Solid Tumors | Oncology | Mar 2028 |
| NCT06781125 | JCXH-211 | Phase 1 | Malignant Solid Tumors | Oncology | Mar 2028 |
Shanghai Juncell Therapeutics Binhui Biopharmaceutical Inventprise LimmaTech Biologics SK Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.